Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses.
about
New viruses for cancer therapy: meeting clinical needsOvercoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint BlockadeEvidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advancesVesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancerTrial Watch:: Oncolytic viruses for cancer therapyMeasles to the Rescue: A Review of Oncolytic Measles VirusPhase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myelomaCycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamstersUnlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacyVirotherapy, gene transfer and immunostimulatory monoclonal antibodies.The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor MicroenvironmentAssessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"?ATN-224 enhances antitumor efficacy of oncolytic herpes virus against both local and metastatic head and neck squamous cell carcinoma.Induction of antiviral genes by the tumor microenvironment confers resistance to virotherapyOncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma.Oncolytic measles virus strains as novel anticancer agents.Glioma virus therapies between bench and bedside.Oncolytic virotherapyHow can we trick the immune system into overcoming the detrimental effects of oncolytic viral therapy to treat glioblastoma?Oncolytic vaccines.Oncolytic viruses and their application to cancer immunotherapyPharmacological modulation of anti-tumor immunity induced by oncolytic viruses.Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.Potential and clinical translation of oncolytic measles viruses.Measles vaccine strains for virotherapy of non-small-cell lung carcinoma.Attenuated measles virus controls pediatric acute B-lineage lymphoblastic leukemia in NOD/SCID mice.Cyclophosphamide enhances antitumor efficacy of oncolytic adenovirus expressing uracil phosphoribosyltransferase (UPRT) in immunocompetent Syrian hamsters.Oncolytic Virotherapy: A Contest between Apples and Oranges.Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy.Oncolytic Viral Therapy for Mesothelioma.BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy.Designing and building oncolytic viruses.Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies.Oncolytic Viruses for Multiple Myeloma Therapy.CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
P2860
Q24567699-731ACC7D-8B47-48D7-AC63-62AA63E351FCQ26769977-547FFAC7-FCB3-433B-A851-DE452030E396Q26775030-0DA447F0-6BCE-4537-A6F9-9A66A09D6D82Q26863779-C72F402D-E28C-4701-9EC4-9E6AB3C2E6A8Q27021839-D8E38437-ECFF-4542-A51C-94027CEBA3A5Q27021951-344047F4-C936-491A-88D3-47EC54A62F81Q28072097-56098DC7-71FE-4078-A5D5-0FFA44975163Q33441321-ABBE48A0-C26E-427F-8142-8CF0DCAE2A92Q33580223-D5E34A5F-325E-4A09-8A8F-FF90140D6804Q35657822-5CFB5387-2CAD-4B92-AE3F-6C130A6B86CDQ36456487-D33D3741-78F1-4506-B0BB-D1C1E7D97E74Q36658280-6D081A66-C316-4095-B720-8DF54A9F357FQ36664268-67A0555E-E133-4D39-98F4-858CF8EB7015Q36664273-7AFF393D-2D17-4D88-A69C-6277CFA1D56FQ37076976-279094D8-7DE3-4B2B-93EB-8F1F1A1280E3Q37123143-2252E516-E661-4732-9195-4D8152141351Q37261017-196877D3-23A9-493C-BA63-2DC4043BB709Q37580510-16635555-EF95-4E8B-BA9B-7699A2DC315EQ38025263-E462B6EF-8922-42A7-B7ED-F0A947AB3A82Q38094806-B39F67CC-C865-47EA-93D6-7BA9475C60D6Q38152474-AE53C6A1-2DD8-4C0C-9D8E-8E17D1FB354AQ38207011-13187A9A-6104-4062-B8EF-5EC90623C8A9Q38237657-D2458B12-A5BA-4C87-8185-8043197A6ACBQ38261256-C2305F5C-1B18-4888-A257-477460A87ADFQ38764947-515AC44D-8B98-47AA-9FB0-49D1890F6165Q38962764-D678F9A1-C2A6-4B53-BF31-36BCCA227C47Q39008033-870A9F1C-0EB3-44C1-9DD5-0B4020C33EA4Q39188023-4C0D1FF5-A8F6-4B0B-A418-E95A404AC52BQ39230055-629E901E-A701-4DB4-AF5A-BDCD302F4D4AQ39387174-1E7A0340-751B-40F8-97AE-91234E621E35Q40051845-1ABFCF6C-AB65-4DE1-B39B-C215769D2D38Q40449206-B788EC19-D544-427F-8262-D13EDA0CA967Q47547386-5F835BB4-4CFB-41CC-A0B1-E19485E881F5Q55085319-5227A263-B9FC-4512-AF28-F79709866337Q55515625-ED20501C-069A-4C7B-BE9A-0E5770EA5773Q58572502-99A869EF-094C-4910-A80B-0C51352E44C6
P2860
Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Using clinically approved cycl ...... response to oncolytic viruses.
@en
Using clinically approved cycl ...... response to oncolytic viruses.
@nl
type
label
Using clinically approved cycl ...... response to oncolytic viruses.
@en
Using clinically approved cycl ...... response to oncolytic viruses.
@nl
prefLabel
Using clinically approved cycl ...... response to oncolytic viruses.
@en
Using clinically approved cycl ...... response to oncolytic viruses.
@nl
P2093
P2860
P356
P1433
P1476
Using clinically approved cycl ...... response to oncolytic viruses.
@en
P2093
A Greenslade
M J Federspiel
S J Russell
P2860
P2888
P304
P356
10.1038/GT.2012.31
P577
2012-04-05T00:00:00Z
P5875
P6179
1034361293